

Chitra M Hosing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7376760/publications.pdf>

Version: 2024-02-01

354
papers

15,614
citations

20759

60
h-index

20900

115
g-index

355
all docs

355
docs citations

355
times ranked

13414
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , 2020, 382, 545-553.	13.9	1,252
2	Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. <i>Blood</i> , 2009, 113, 5720-5726.	0.6	697
3	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017, 25, 285-295.	3.7	498
4	Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. <i>Blood</i> , 2013, 122, 2965-2973.	0.6	470
5	Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4199-4206.	0.8	433
6	Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture. <i>New England Journal of Medicine</i> , 2012, 367, 2305-2315.	13.9	430
7	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , 2018, 378, 35-47.	13.9	417
8	Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 3363-3376.	3.9	399
9	Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 295-308.	2.0	305
10	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i> , 2008, 111, 5530-5536.	0.6	294
11	Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. <i>Blood</i> , 2006, 107, 3074-3080.	0.6	265
12	Tumor necrosis factor- α blockade for the treatment of acute GVHD. <i>Blood</i> , 2004, 104, 649-654.	0.6	253
13	Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. <i>Bone Marrow Transplantation</i> , 2008, 41, 771-778.	1.3	233
14	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1835-1844.	2.0	227
15	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1975-1981.	2.0	207
16	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. <i>Blood</i> , 2009, 113, 4144-4152.	0.6	196
17	Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 178-185.	2.0	192
18	Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2005, 130, 409-417.	1.2	184

#	ARTICLE	IF	CITATIONS
19	Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. <i>Blood</i> , 2003, 102, 3052-3059.	0.6	167
20	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 457-466.	1.2	158
21	Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 122, 128-134.	1.2	157
22	Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 718-723.	2.0	150
23	Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and SÅ©zary Syndrome. <i>Journal of Clinical Oncology</i> , 2010, 28, 2365-2372.	0.8	149
24	Steroid-Refractory Acute GVHD: Predictors and Outcomes. <i>Advances in Hematology</i> , 2011, 2011, 1-8.	0.6	146
25	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. <i>Blood</i> , 2003, 102, 3829-3836.	0.6	143
26	Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. <i>Haematologica</i> , 2008, 93, 257-264.	1.7	141
27	Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. <i>Cancer</i> , 2007, 109, 2481-2489.	2.0	138
28	Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkinâ€™s Lymphomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 2240-2247.	0.8	127
29	Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1872-1880.	1.3	125
30	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. <i>Blood Advances</i> , 2020, 4, 5580-5588.	2.5	122
31	Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. <i>Experimental Hematology</i> , 2004, 32, 28-35.	0.2	119
32	Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. <i>Blood</i> , 2015, 125, 2885-2892.	0.6	118
33	Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of High-Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome Using Reduced-Intensity Conditioning with Fludarabine and Melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 454-462.	2.0	117
34	Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. <i>Bone Marrow Transplantation</i> , 2007, 40, 125-136.	1.3	117
35	Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. <i>Bone Marrow Transplantation</i> , 2005, 35, 943-951.	1.3	113
36	Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. <i>Blood</i> , 2014, 123, 3263-3268.	0.6	110

#	ARTICLE	IF	CITATIONS
37	Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 108-114.	2.0	109
38	Nonmyeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients With Non-Hodgkin's Lymphoma Whose Disease Has Failed a Prior Autologous Transplantation. <i>Journal of Clinical Oncology</i> , 2004, 22, 2419-2423.	0.8	106
39	The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 119, 2738-2745.	0.6	106
40	A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1555-1562.	2.0	104
41	Hyperacute GVHD: risk factors, outcomes, and clinical implications. <i>Blood</i> , 2007, 109, 2751-2758.	0.6	98
42	Nonmyeloablative allogeneic transplantation with or without 90Yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. <i>Blood</i> , 2012, 119, 6373-6378.	0.6	97
43	Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. <i>American Journal of Hematology</i> , 2009, 84, 335-337.	2.0	93
44	Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 893-900.	2.0	93
45	Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1490-1496.	2.0	90
46	Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. <i>Annals of Oncology</i> , 2015, 26, 2490-2495.	0.6	87
47	Detection and Control of a Nosocomial Respiratory Syncytial Virus Outbreak in a Stem Cell Transplantation Unit: The Role of Palivizumab. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1265-1271.	2.0	81
48	IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. <i>Blood</i> , 2016, 128, 1346-1361.	0.6	81
49	The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 176, 750-758.	1.2	78
50	Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. <i>Blood</i> , 2009, 114, 2884-2887.	0.6	76
51	Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. <i>Stem Cells Translational Medicine</i> , 2014, 3, 1435-1443.	1.6	75
52	Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	2.0	75
53	Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 118-122.	0.6	74
54	Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. <i>Cancer</i> , 2006, 106, 1084-1089.	2.0	69

#	ARTICLE	IF	CITATIONS
55	Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease: Does It Work?. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 37-40.	2.0	68
56	Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 812-816.	2.0	68
57	Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 542-548.	2.0	68
58	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e266-e275.	2.2	68
59	Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial. <i>Journal of Rheumatology</i> , 2013, 40, 455-460.	1.0	67
60	Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1059-1064.	2.0	65
61	Transplant-Associated Microangiopathy in Patients Receiving Tacrolimus Following Allogeneic Stem Cell Transplantation: Risk Factors and Response to Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 469-477.	2.0	64
62	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. <i>British Journal of Haematology</i> , 2015, 168, 646-653.	1.2	64
63	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1232-1236.	2.0	64
64	Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. <i>Bone Marrow Transplantation</i> , 2002, 30, 543-546.	1.3	63
65	Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2013, 160, 798-805.	1.2	63
66	Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2002, 13, 450-459.	0.6	62
67	Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2005, 36, 157-162.	1.3	62
68	Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 410-417.	2.0	61
69	Posttransplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 444-455.	1.2	61
70	Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Ex vivo Expansion. <i>Journal of Immunotherapy</i> , 2010, 33, 684-696.	1.2	58
71	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 47-53.	2.0	58
72	Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. <i>Leukemia</i> , 2008, 22, 258-264.	3.3	57

#	ARTICLE	IF	CITATIONS
73	The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 319-326.	0.2	55
74	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. <i>Blood</i> , 2016, 128, 297-312.	0.6	54
75	Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. <i>Blood</i> , 2007, 110, 3456-3462.	0.6	53
76	Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2007, 21, 2540-2544.	3.3	53
77	An Adaptive Randomized Trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in Patients With Cancer and Respiratory Syncytial Virus Infection. <i>Journal of Infectious Diseases</i> , 2012, 206, 1367-1371.	1.9	52
78	General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1284-1290.	2.0	51
79	Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2013, 48, 666-670.	1.3	50
80	Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. <i>Frontiers in Medicine</i> , 2015, 2, 89.	1.2	50
81	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	2.0	48
82	Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2006, 133, 533-537.	1.2	47
83	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 555-559.	2.0	46
84	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
85	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1440-1448.	2.0	44
86	High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. <i>Annals of Oncology</i> , 2008, 19, 1166-1171.	0.6	43
87	Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Haematologica</i> , 2009, 94, 249-257.	1.7	43
88	Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1819-1826.	2.0	43
89	High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1677-1686.	2.0	43
90	West Nile Encephalitis in 2 Hematopoietic Stem Cell Transplant Recipients: Case Series and Literature Review. <i>Clinical Infectious Diseases</i> , 2003, 37, 1044-1049.	2.9	41

#	ARTICLE	IF	CITATIONS
91	Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2007, 39, 279-283.	1.3	41
92	Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. <i>Bone Marrow Transplantation</i> , 2008, 42, 67-69.	1.3	41
93	Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. <i>European Journal of Haematology</i> , 2018, 101, 389-398.	1.1	41
94	Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1066-1072.	2.0	40
95	Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 412-420.	2.0	40
96	Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2006, 38, 421-426.	1.3	39
97	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1401-1407.	2.0	39
98	A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. <i>Cancer</i> , 2012, 118, 2507-2515.	2.0	39
99	Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. <i>Blood</i> , 2020, 135, 449-452.	0.6	39
100	Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. <i>Bone Marrow Transplantation</i> , 2013, 48, 1218-1223.	1.3	38
101	Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 493-498.	2.0	38
102	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1265-1270.	2.0	37
103	Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Scleroderma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e83-e93.	0.2	37
104	High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 991-994.	2.0	36
105	Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β_2 -adrenergic receptor. <i>Brain, Behavior, and Immunity</i> , 2018, 68, 66-75.	2.0	36
106	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 906-912.	2.0	35
107	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3845-3856.	3.2	35
108	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1227-1232.	2.0	34

#	ARTICLE	IF	CITATIONS
109	Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2166-2171.	2.0	34
110	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1122-1129.	2.0	33
111	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. <i>Haematologica</i> , 2015, 100, 1361-1370.	1.7	32
112	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	0.8	32
113	Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 294-302.	0.8	31
114	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. <i>Cancer</i> , 2017, 123, 629-637.	2.0	31
115	Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 472-476.	0.2	28
116	Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. <i>Journal of Clinical Oncology</i> , 2015, 33, 1557-1563.	0.8	27
117	High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2011, 86, 954-956.	2.0	26
118	Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. <i>Bone Marrow Transplantation</i> , 2012, 47, 212-216.	1.3	26
119	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2159-2164.	2.0	26
120	Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2008, 142, 786-792.	1.2	25
121	Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>American Journal of Hematology</i> , 2012, 87, 272-276.	2.0	25
122	Peripheral blood stem cell yield calculated using preapheresis absolute $CD34^{+}$ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers. <i>Transfusion</i> , 2014, 54, 1081-1087.	0.8	25
123	Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes. <i>Cancer</i> , 2017, 123, 2329-2337.	2.0	25
124	Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 686-694.	2.0	24
125	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 285-292.	2.0	24
126	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 601-606.	1.3	24

#	ARTICLE	IF	CITATIONS
127	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019, 54, 839-848.	1.3	24
128	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	2.2	23
129	Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2005, 80, 43-45.	2.0	22
130	Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. <i>Leukemia and Lymphoma</i> , 2012, 53, 1239-1241.	0.6	22
131	Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte colony stimulating factor for peripheral blood progenitor cell mobilization. <i>American Journal of Hematology</i> , 2013, 88, 754-757.	2.0	22
132	Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1359-1366.	2.0	22
133	Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2197-2203.	2.0	22
134	Acute Kidney Injury in Patients with Systemic Sclerosis Participating in Hematopoietic Cell Transplantation Trials in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 674-681.	2.0	21
135	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e1-e5.	0.2	21
136	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
137	Is a matched unrelated donor search needed for all allogeneic transplant candidates?. <i>Blood Advances</i> , 2018, 2, 2254-2261.	2.5	21
138	Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 901-906.	0.6	20
139	Augmentation of Blood Dendritic Cells by Extracorporeal Photopheresis in Patients with Leukemic Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2098-2100.	0.3	20
140	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	2.0	20
141	Hematopoietic Stem Cell Mobilization with G-CSF. , 2012, 904, 37-47.		19
142	Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1333-1337.	2.0	19
143	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2022, 57, 51-56.	1.3	19
144	Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. <i>Transfusion</i> , 2011, 51, 1300-1313.	0.8	18

#	ARTICLE	IF	CITATIONS
145	A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1453-1458.	2.0	18
146	False-positive HIV nucleic acid amplification testing during CAR T-cell therapy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 305-307.	0.8	18
147	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. <i>European Journal of Haematology</i> , 2017, 99, 532-535.	1.1	18
148	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 430.e1-430.e7.	0.6	18
149	Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. <i>Bone Marrow Transplantation</i> , 2021, 56, 1316-1324.	1.3	18
150	Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S63-S70.	2.0	17
151	Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1841-1845.	2.0	17
152	CARs in Chronic Lymphocytic Leukemia – Ready to Drive. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 60-70.	1.2	17
153	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	0.6	17
154	Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e41-e50.	0.2	17
155	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1439-1445.	2.0	17
156	Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1094-1099.	2.0	16
157	Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1792-1800.	2.0	16
158	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2016, 91, E442-7.	2.0	16
159	Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 2444.	2.2	16
160	Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. <i>Oncotarget</i> , 2016, 7, 63829-63838.	0.8	16
161	High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1290-1294.	0.6	15
162	Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 325-331.	0.5	15

#	ARTICLE	IF	CITATIONS
163	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 961-965.	2.0	15
164	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
165	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1146-1154.	0.4	15
166	A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2018, 103, e416-e418.	1.7	15
167	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 442-452.	0.6	15
168	Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus. <i>Transfusion</i> , 2019, 59, 3519-3524.	0.8	15
169	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 505-514.	2.0	15
170	A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). <i>Blood</i> , 2020, 136, 40-41.	0.6	15
171	Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 393-394.	1.3	14
172	Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. <i>Bone Marrow Transplantation</i> , 2013, 48, 26-31.	1.3	14
173	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 581-587.	2.0	14
174	Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1329-1333.	1.5	14
175	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 689-695.	0.6	14
176	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2006, 108, 315-315.	0.6	14
177	Utility of routine surveillance blood cultures in asymptomatic allogeneic hematopoietic stem cell transplant recipients with indwelling central venous catheters at a comprehensive cancer center. <i>American Journal of Infection Control</i> , 2014, 42, 1084-1088.	1.1	13
178	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2021, 106, 3211-3214.	1.7	13
179	Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. <i>Blood</i> , 2008, 112, 154-154.	0.6	13
180	Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 533-535.	0.6	12

#	ARTICLE	IF	CITATIONS
181	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 122-128.	0.2	12
182	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas: long term results. <i>British Journal of Haematology</i> , 2017, 178, 561-570.	1.2	12
183	Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S261-S265.	1.4	11
184	Stem cell transplantation outcomes in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 366-371.	0.6	11
185	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 3568-3575.	2.0	11
186	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥ 75 years. <i>Leukemia and Lymphoma</i> , 2019, 60, 3536-3543.	0.6	11
187	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1039-1044.	2.0	11
188	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. <i>Bone Marrow Transplantation</i> , 2021, 56, 2005-2012.	1.3	11
189	Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitive Follicular Lymphoma (FL). <i>Blood</i> , 2005, 106, 48-48.	0.6	11
190	Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. <i>Blood</i> , 2013, 122, 691-691.	0.6	11
191	Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. <i>Leukemia and Lymphoma</i> , 2012, 53, 499-502.	0.6	10
192	Low rate of infusional toxicity after expanded cord blood transplantation. <i>Cytotherapy</i> , 2014, 16, 1153-1157.	0.3	10
193	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	3.2	10
194	Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. <i>Haematologica</i> , 2020, 106, 269-274.	1.7	10
195	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1003.e1-1003.e13.	0.6	10
196	First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. <i>Blood</i> , 2013, 122, 166-166.	0.6	10
197	Is there an expiration date for a cord blood unit in storage?. <i>Bone Marrow Transplantation</i> , 2014, 49, 1109-1112.	1.3	9
198	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. <i>European Journal of Haematology</i> , 2016, 97, 342-347.	1.1	9

#	ARTICLE	IF	CITATIONS
199	Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. <i>Bone Marrow Transplantation</i> , 2018, 53, 315-325.	1.3	9
200	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 639-646.	0.6	9
201	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Cancer</i> , 2021, 127, 1598-1605.	2.0	9
202	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. <i>Haematologica</i> , 2022, 107, 899-908.	1.7	9
203	Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 3991-3991.	0.6	9
204	Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e105-e109.	0.2	8
205	Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. <i>Blood</i> , 2017, 129, 3031-3033.	0.6	8
206	Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. <i>Leukemia and Lymphoma</i> , 2016, 57, 2644-2652.	0.6	7
207	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. <i>British Journal of Haematology</i> , 2017, 177, 567-577.	1.2	7
208	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
209	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e51-e61.	0.2	7
210	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. <i>Blood Advances</i> , 2020, 4, 1296-1306.	2.5	7
211	The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 47-57.	1.2	6
212	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. <i>Transfusion</i> , 2017, 57, 1052-1057.	0.8	6
213	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 263-268.	1.1	6
214	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. <i>Annals of Hematology</i> , 2019, 98, 2233-2235.	0.8	6
215	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 913.e1-913.e12.	0.6	6
216	Reduced-Intensity Conditioning Regimen with BEAM/Rituximab for Patients with Refractory Non-Hodgkin's Lymphomas. <i>Blood</i> , 2004, 104, 2315-2315.	0.6	6

#	ARTICLE	IF	CITATIONS
217	Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2270-2270.	0.6	6
218	Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. <i>Blood Advances</i> , 2022, 6, 2267-2274.	2.5	6
219	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 395.e1-395.e11.	0.6	6
220	Interleukin-2 and granulocyte "macrophage" colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. <i>International Journal of Hematology</i> , 2009, 90, 627-634.	0.7	5
221	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and "Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1413-1417.	2.0	5
222	Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. <i>Leukemia Research</i> , 2016, 47, 100-108.	0.4	5
223	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 36-42.	0.2	5
224	Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. <i>American Journal of Hematology</i> , 2019, 94, E176-E180.	2.0	5
225	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	2.0	5
226	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1746-1749.	1.3	5
227	Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. <i>Blood</i> , 2007, 110, 620-620.	0.6	5
228	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. <i>Blood</i> , 2012, 120, 4200-4200.	0.6	5
229	Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). <i>Blood</i> , 2013, 122, 410-410.	0.6	5
230	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. <i>Blood</i> , 2015, 126, 854-854.	0.6	5
231	Treatment of Relapsing Refractory Diffuse Large Cell Lymphoma After Matched Unrelated Donor Bone Marrow Transplant with Immunosuppression Withdrawal and Rituximab. <i>Leukemia and Lymphoma</i> , 2003, 44, 829-832.	0.6	4
232	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1478-1484.	0.6	4
233	Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1529-1531.	2.0	4
234	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. <i>Leukemia and Lymphoma</i> , 2018, 59, 515-518.	0.6	4

#	ARTICLE	IF	CITATIONS
235	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. American Journal of Hematology, 2018, 94, E72-E74.	2.0	4
236	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1077-1083.	2.0	4
237	Incidence of viral and fungal complications after utilization of alternative donor sources in hematopoietic cell transplantation. Pharmacotherapy, 2020, 40, 773-787.	1.2	4
238	Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplantation, 2021, 56, 745-748.	1.3	4
239	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. Blood, 2016, 128, 3554-3554.	0.6	4
240	Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.. Blood, 2005, 106, 1123-1123.	0.6	4
241	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,. Blood, 2011, 118, 4118-4118.	0.6	4
242	Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplantation and Cellular Therapy, 2022, 28, 501.e1-501.e7.	0.6	4
243	A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. Journal of Blood Medicine, 2010, 1, 49.	0.7	3
244	Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 1059-1063.	2.0	3
245	Epstein-Barr virus specific cytotoxic T lymphocytes for the treatment of severe epstein-Barr virus mucocutaneous ulcer. British Journal of Haematology, 2020, 189, e33-e36.	1.2	3
246	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 404.e1-404.e5.	0.6	3
247	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. American Journal of Hematology, 2021, 96, E455-E457.	2.0	3
248	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A New Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2005, 106, 1159-1159.	0.6	3
249	Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin's Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.. Blood, 2005, 106, 44-44.	0.6	3
250	Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.. Blood, 2006, 108, 2460-2460.	0.6	3
251	Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).. Blood, 2007, 110, 948-948.	0.6	3
252	Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience. Blood, 2014, 124, 1245-1245.	0.6	3

#	ARTICLE	IF	CITATIONS
253	Allogeneic transplantation for myelofibrosis: Benefit of dose intensity.. Journal of Clinical Oncology, 2013, 31, 7011-7011.	0.8	3
254	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan±clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	3
255	Diffuse Large B-cell Non-Hodgkin's Lymphoma Presenting as a Vaginal Mass in a Patient With a History of Intestinal Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 204-208.	0.6	2
256	Progress in Novel Cellular Therapy Options for Chronic Lymphocytic Leukemia: The MD Anderson Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S18-S22.	0.2	2
257	Donor Cell-Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e151-e155.	0.2	2
258	Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplantation, 2021, 56, 278-281.	1.3	2
259	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematologica, 2021, 144, 74-81.	0.7	2
260	Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking. Cytotherapy, 2021, 23, 1029-1035.	0.3	2
261	Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation. European Journal of Haematology, 2021, 107, 634-641.	1.1	2
262	Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.. Blood, 2005, 106, 660-660.	0.6	2
263	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood, 2008, 112, 3320-3320.	0.6	2
264	Stem Cell Transplantation with 90Yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.. Blood, 2009, 114, 868-868.	0.6	2
265	Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 4321-4321.	0.6	2
266	Efficacy of "Off-the-Shelf", Commercially-Available, Third-Party Mesenchymal Stem Cells (MSC) in Ex Vivo Cord Blood (CB) Co-Culture Expansion.. Blood, 2007, 110, 4106-4106.	0.6	2
267	High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma. Blood, 2008, 112, 4452-4452.	0.6	2
268	Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Blood, 2021, 138, 482-482.	0.6	2
269	Autologous Hematopoietic Stem Cell Transplantation in Light Chain Amyloidosis (AL) With Renal Involvement. Biology of Blood and Marrow Transplantation, 2013, 19, S234-S235.	2.0	1
270	Granulocyte concentrates from a single high-yield apheresis can be split to support multiple patients. Leukemia and Lymphoma, 2014, 55, 2577-2583.	0.6	1

#	ARTICLE	IF	CITATIONS
271	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Reports in Oncology, 2018, 11, 721-728.	0.3	1
272	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 243.e1-243.e6.	0.6	1
273	Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.. Blood, 2004, 104, 734-734.	0.6	1
274	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2006, 108, 3090-3090.	0.6	1
275	Two-Year Follow-Up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin's Lymphoma: Comparable Outcome with Matched Related and Unrelated Donors.. Blood, 2006, 108, 3115-3115.	0.6	1
276	HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT).. Blood, 2006, 108, 3125-3125.	0.6	1
277	Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2R β null (NSG) Mice as a Model.. Blood, 2009, 114, 2370-2370.	0.6	1
278	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. Blood, 2011, 118, 246-246.	0.6	1
279	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood, 2011, 118, 333-333.	0.6	1
280	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.. Blood, 2012, 120, 3094-3094.	0.6	1
281	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5884-5884.	0.6	1
282	Allogeneic hematopoietic cell transplantation (alloHCT) in diffuse large B-cell lymphoma (DLBCL) after nonmyeloablative (NMA) or reduced-intensity (RIC) conditioning: Long-term outcome in 116 patients.. Journal of Clinical Oncology, 2013, 31, 8561-8561.	0.8	1
283	Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM).. Blood, 2005, 106, 2923-2923.	0.6	1
284	A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.. Blood, 2007, 110, 3032-3032.	0.6	1
285	Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. Blood, 2008, 112, 2999-2999.	0.6	1
286	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).. Blood, 2009, 114, 2310-2310.	0.6	1
287	Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 4354-4354.	0.6	1
288	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. Blood, 2012, 120, 3129-3129.	0.6	1

#	ARTICLE	IF	CITATIONS
289	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2019, 134, 257-257.	0.6	1
290	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucl (axi-cel) for Non-Hodgkin Lymphoma (NHL). Blood, 2020, 136, 17-18.	0.6	1
291	Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. Blood, 2020, 136, 29-30.	0.6	1
292	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood, 2020, 136, 9-10.	0.6	1
293	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 24-25.	0.6	1
294	Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability. JMIR Formative Research, 2022, 6, e29393.	0.7	1
295	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 307.e1-307.e8.	0.6	1
296	Hematopoietic stem cell transplantation for the management of follicular lymphoma. Stem Cells and Cloning: Advances and Applications, 2010, 3, 69.	2.3	0
297	Rhinovirus Infections (RhV) in 233 Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
298	Effect of High-Dose Rituximab on Peripheral Blood Stem Cell Mobilization in Intermediate Grade Non-Hodgkin's Lymphomas.. Blood, 2004, 104, 2877-2877.	0.6	0
299	A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen eith T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).. Blood, 2004, 104, 5184-5184.	0.6	0
300	Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma.. Blood, 2004, 104, 3329-3329.	0.6	0
301	Campath-IH Combined with Fludarabine/Cyclophosphamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin's Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.. Blood, 2005, 106, 2902-2902.	0.6	0
302	Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.. Blood, 2005, 106, 2019-2019.	0.6	0
303	Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin's Lymphoma.. Blood, 2006, 108, 5316-5316.	0.6	0
304	High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin's Lymphoma (NHL) in Patients over 65 Years of Age.. Blood, 2006, 108, 3059-3059.	0.6	0
305	Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma.. Blood, 2006, 108, 5422-5422.	0.6	0
306	In Utero Is Superior to Ex Utero Cord Blood Collection.. Blood, 2006, 108, 3645-3645.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.. Blood, 2006, 108, 3101-3101.	0.6	0
308	Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.. Blood, 2007, 110, 5126-5126.	0.6	0
309	Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin's Lymphomas (NHLs).. Blood, 2007, 110, 1900-1900.	0.6	0
310	A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants.. Blood, 2007, 110, 3051-3051.	0.6	0
311	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. Blood, 2007, 110, 48-48.	0.6	0
312	Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation.. Blood, 2007, 110, 3002-3002.	0.6	0
313	Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).. Blood, 2007, 110, 5015-5015.	0.6	0
314	Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.. Blood, 2008, 112, 1128-1128.	0.6	0
315	Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood, 2008, 112, 3298-3298.	0.6	0
316	Foxp3 Expression Is Induced in Peripheral Blood Mononuclear Cells from Patients with CTCL and GVHD after Extracorporeal Photopheresis. Blood, 2008, 112, 2912-2912.	0.6	0
317	Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. Blood, 2008, 112, 3306-3306.	0.6	0
318	Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 4326-4326.	0.6	0
319	Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood, 2008, 112, 799-799.	0.6	0
320	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. Blood, 2009, 114, 3213-3213.	0.6	0
321	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.. Blood, 2009, 114, 2309-2309.	0.6	0
322	Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma.. Blood, 2009, 114, 1227-1227.	0.6	0
323	Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood, 2010, 116, 3510-3510.	0.6	0
324	Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood, 2010, 116, 2341-2341.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant.. Blood, 2010, 116, 1322-1322.	0.6	0
326	12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,. Blood, 2011, 118, 4138-4138.	0.6	0
327	Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2855-2855.	0.6	0
328	Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts,. Blood, 2011, 118, 4047-4047.	0.6	0
329	Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. Blood, 2011, 118, 3106-3106.	0.6	0
330	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood, 2011, 118, 2006-2006.	0.6	0
331	Stem Cell Transplantation for Non-Hodgkinâ€™s Lymphomas. , 2013, , 371-402.		0
332	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). Blood, 2013, 122, 2142-2142.	0.6	0
333	Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 2880-2880.	0.6	0
334	Autologous stem cell transplantation in dialysis-dependent myeloma patients.. Journal of Clinical Oncology, 2014, 32, 8601-8601.	0.8	0
335	Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.. Journal of Clinical Oncology, 2014, 32, 8538-8538.	0.8	0
336	The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood, 2015, 126, 3984-3984.	0.6	0
337	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood, 2018, 132, 4607-4607.	0.6	0
338	Hematopoietic Stem Cell Transplantation for Rare Hematological Malignancies. , 2019, , 263-277.		0
339	Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. Blood, 2019, 134, 3596-3596.	0.6	0
340	Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood, 2019, 134, 4598-4598.	0.6	0
341	The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. The Internet Journal of Hematology, 2009, 7, .	0.5	0
342	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood, 2021, 138, 1802-1802.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 1779-1779.	0.6	0
344	Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood, 2020, 136, 11-13.	0.6	0
345	PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood, 2020, 136, 6-7.	0.6	0
346	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 18-19.	0.6	0
347	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 22-22.	0.6	0
348	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18.	0.6	0
349	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 20-21.	0.6	0
350	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. Blood, 2020, 136, 10-11.	0.6	0
351	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood, 2020, 136, 23-24.	0.6	0
352	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. Blood, 2020, 136, 27-28.	0.6	0
353	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. Blood, 2020, 136, 40-41.	0.6	0
354	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine $\hat{\pm}$ Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2020, 136, 37-38.	0.6	0